Please login to the form below

Not currently logged in
Email:
Password:

Just Health PR wins Caris Life Sciences brief

Bioscience company to launches its tumour profiling technology in Europe

Just Health PR has been appointed by US bioscience company Caris Life Sciences to help introduce their tumour profiling technology to European markets.

Caris' molecular intelligence (MI) service provides oncologists with clinically actionable, individualised treatment information for solid tumours.

Using a combination of technologies, including next-generation sequencing (NGS), Caris sifts a database of peer-review and published cancer research papers, in order to correlate specific biomarkers to positive drug responses.

By comparing the genetic and molecular makeup unique to each patient's tumour with data from existing clinical studies, GPs can determine the course of treatment likely to be most effective for the individual patient.

Leading the Just Health PR push will be the agency's head of political relations, Jon Spiers, who said: "This is an incredibly fast-moving and innovative area of medicine which is of great interest to politicians and policymakers.

"We are thrilled to be working on a technology, which has the potential to revolutionise the way we treat cancer."

Because MI is neither a treatment nor a diagnostic, there is no clear measure for assessing its utility within the NHS. However, the Just team has begun talks with the Department of Health, the Technology Strategy Board, the NHS Technology Adoption Centre and the Downing Street Policy Unit to determine how the health service might adopt the technology.

12th February 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics